telmisartan/hydrochlorothiazide / Generic mfg. - LARVOL DELTA

Lichenoid Drug Eruption due to Telmisartan-Hydrochlorothiazide Combination Progressing to Bullous Pemphigoid: A Case Report. (PubMed, J Dermatol) - No abstract available

Journal • Bullous Pemphigoid • Dermatology • Dermatopathology • Immunology • Lichen Planus

Bioequivalence and Food Effect Assessment of Two Fixed-Dose Combination Formulations of Telmisartan-Hydrochlorothiazide Tablets in Chinese Healthy Subjects. (PubMed, Clin Transl Sci) - "Two telmisartan-hydrochlorothiazide FDC formulations were bioequivalent in healthy Chinese subjects in both fasted and fed states. All treatments were well tolerated."

Clinical • Journal

MANAGEMENT OF RISKS OF ADVERSE DRUG REACTIONS ACCORDING TO ADR REPORT FORM DATA FROM LVIV REGION HEALTHCARE FACILITIES IN 2022. (PubMed, Georgian Med News) - "Within the penicillin class, amoxicillin potentiated by clavulanate (67%) and amoxicillin (29%) were the dominant drugs showing the highest incidence rate of adverse reactions. Among cephalosporins, ceftriaxone (46%) and cefixime (15%) were found to take the lead in terms of adverse reaction frequency...The leading medications in the angiotensin-converting enzyme inhibitors category were enalapril (47%) and the combination of lisinopril with hydrochlorothiazide (24%)...In the category of CCB drugs, amlodipine (66%) and nifedipine (20%) held the leading positions...Analysis of adverse drug reactions reports for angiotensin II receptor blockers showed no cases of cough with valsartan and telmisartan-hydrochlorothiazide combination...Among all the non-steroidal anti-inflammatory drugs prescribed to patients in the Lviv region in 2022, the highest number of adverse reactions was associated with the administration of diclofenac, ibuprofen, paracetamol, and nimesulide, causing..."

Adverse drug reaction • Journal • Allergy • Cardiovascular • Cough • Gastroenterology • Gastrointestinal Disorder • Immunology • Respiratory Diseases

Comparison of the Medication Adherence of Patients Treated With Telmisartan/Hydrochlorothiazide or Telmisartan/Amlodipine Fixed Dose Combination (FDC) Versus Double-pill Combination Therapy in Real-world Japanese Therapeutic Practice (clinicaltrials.gov) - P=N/A | N=0 | Withdrawn | Sponsor: Boehringer Ingelheim | N=3275 ➔ 0 | Not yet recruiting ➔ Withdrawn

Combination therapy • Enrollment change • Real-world evidence • Trial withdrawal • Cardiovascular • Hypertension

A Bioequivalence Study Between Telmione Plus 80/12.5mg and Micardis Plus 80/12.5 mg in Healthy Adult Volunteers (clinicaltrials.gov) - P1 | N=46 | Completed | Sponsor: HK inno.N Corporation | Recruiting ➔ Completed | Trial completion date: Aug 2022 ➔ Oct 2021

Trial completion • Trial completion date • Hypertension

Comparison of the Medication Adherence of Patients Treated With Telmisartan/Hydrochlorothiazide or Telmisartan/Amlodipine Fixed Dose Combination (FDC) Versus Double-pill Combination Therapy in Real-world Japanese Therapeutic Practice (clinicaltrials.gov) - P=N/A; N=3275; Not yet recruiting; Sponsor: Boehringer Ingelheim; Trial completion date: Jan 2022 ➔ Jul 2022; Trial primary completion date: Jan 2022 ➔ Jul 2022

Clinical • Combination therapy • Real-world evidence • Trial completion date • Trial primary completion date • Hypertension

A Bioequivalence Study Between Telmione Plus 80/12.5mg and Micardis Plus 80/12.5 mg in Healthy Adult Volunteers (clinicaltrials.gov) - P1; N=46; Recruiting; Sponsor: HK inno.N Corporation

Clinical • New P1 trial • Hypertension

An eco-friendly modified methodology for the resolution of binary pharmaceutical mixtures based on self-deconvolution of the UV spectrophotometric spectra in the Fourier domain: Application of Fourier self-deconvolution in UV spectroscopy. (PubMed, Spectrochim Acta A Mol Biomol Spectrosc) - "The utilized approach managed to resolve the binary mixtures of telmisartan/hydrochlorothiazide and ramipril/hydrochlorothiazide in their pharmaceutical dosage forms...The developed FSD approach was validated as per the ICH recommendations regarding the accuracy, precision, linearity, selectivity, and limits of detection and quantitation. The recoveries obtained from the proposed approach were statistically compared with the corresponding reported methods and found no statistical difference between the obtained results."

Journal

Comparison of the Medication Adherence of Patients Treated With Telmisartan/Hydrochlorothiazide or Telmisartan/Amlodipine Fixed Dose Combination (FDC) Versus Double-pill Combination Therapy in Real-world Japanese Therapeutic Practice (clinicaltrials.gov) - P=N/A; N=3275; Not yet recruiting; Sponsor: Boehringer Ingelheim; Trial completion date: Jul 2021 ➔ Jan 2022; Trial primary completion date: Jul 2021 ➔ Jan 2022

Trial completion date • Trial primary completion date • Hypertension

Risk and DoE-Based DMAIC Principle to the Multipurpose-RP-HPLC Method for Synchronous Estimation of Anti-Hypertensive Drugs Using AQbD approach. (PubMed, J AOAC Int) - "Development of a multipurpose-RPLC method for synchronous estimation of antihypertensive products of telmisartan to save time, cost, and solvent for analysis. Application of the developed method for synchronous estimation of seven different anti-hypertensive products."

Journal • Hypertension

Advanced eco-friendly UV spectrophotometric approach for resolving overlapped spectral signals of antihypertensive agents in their binary and tertiary pharmaceutical dosage form. (PubMed, Spectrochim Acta A Mol Biomol Spectrosc) - "This work presents novel and green spectrophotometric methods for the concurrent analysis of Amlodipine (AML), Telmisartan (TEL), Hydrochlorothiazide (HCTZ), and Chlorthalidone (CLO) in their pharmaceutical dosage form. Furthermore, the introduced methods were ensured by the standard addition technique. Finally, the obtained results were statistically compared by the reported spectrophotometric methods, showing no significant difference concerning precision and accuracy."

Journal • Acute Myelogenous Leukemia • Cardiovascular • Hypertension